The European Medicines Agency (EMA) has made a decision regarding the case-by-case use of a medicine.
1 report, 1 independent
Updated Jun 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The European Medicines Agency (EMA) has made a decision regarding the case-by-case use of a medicine.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The European Medicines Agency (EMA) is evaluating experimental treatments that were developed in Japan.Sub-event
EMA decided on the case-by-case use of medicine.1 source
Keep exploring
The entities involved
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
- Japan
Related events
- Oncopeptides AB's drug received a positive opinion from the EMA, leading to the European Commission making a final decision for the EU market.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- EMA adopted a positive opinion and the European Commission granted marketing authorization for the drug Hopledo.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Emer Cooke has been named the executive director at the European Medicines Agency (EMA).